Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Bone Marrow Transplantation volume 54, pages 1515–1517 (2019)Cite this article

Subjects

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma [1]. The recent recognition of IVLBCL has enabled a rapid and definite diagnosis. In addition, the clinical outcome of patients with IVLBCL has improved through the introduction of rituximab; however, the 2-year progression-free survival (PFS) rate of 56% is still unsatisfactory [2, 3]. Several reports have shown that autologous peripheral blood stem cell transplantation (auto-PBSCT) following high-dose chemotherapy (HDC) may be an effective against IVLBCL [2, 4, 5]. On the other hand, because of the small sample size in each report, there are not enough data supporting the efficacy of auto-PBSCT against IVLBCL. The objective of this study is to investigate a possible role of consolidative auto-PBSCT following HDC in the frontline treatment of patients with IVLBCL by analyzing the data with large number in the rituximab era.

We retrospectively analyzed that clinical data of the Transplant Registry Unified Management Program (TRUMP), which is a registry database of the Japan Society for Hematopoietic Cell Transplantation (JHSCT). Because the TRUMP data regarding the use of rituximab were incomplete in the induction therapy, we analyzed the data of patients with IVLBCL who achieved a first complete response (CR1) or first partial response (PR1) at auto-PBSCT after 2003, when rituximab was approved for DLBCL in Japan. Overall survival (OS) was defined as the time from transplantation until death, and data from patients who remained alive at the time of the last follow-up were censored. PFS was defined as the time from auto-PBSCT to disease progression or death from any cause. Non-relapse mortality (NRM) was defined as any death without relapse or progression of IVLBCL. Death without relapse was defined as a competing event in calculating the cumulative incidence of relapse. This study was approved by the data management committees of the JSHCT as well as the institutional ethics committee of the Kyushu University Graduate School of Medical Sciences.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Asada N, Odawara J, Kimura S, Aoki T, Yamakura M, Takeuchi M, et al. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc. 2007;82:1525–7.

    Article  Google Scholar 

  2. Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol. 2008;26:3189–95.

    Article  CAS  Google Scholar 

  3. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008;26:5134–6.

    Article  Google Scholar 

  4. Kato K, Ohno Y, Kamimura T, Kusumoto H, Tochigi T, Jinnouchi F, et al. Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma. Bone Marrow Transplant. 2014;49:1543–4.

    Article  CAS  Google Scholar 

  5. Meissner J, Finel H, Dietrich S, Boumendil A, Kanfer E, Laboure G, et al. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. Bone Marrow Transplant. 2017;52:650–2.

    Article  CAS  Google Scholar 

  6. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101:1480–6.

    Article  CAS  Google Scholar 

  7. Murase T, Nakamura S, Kawauchi K, Matsuzaki H, Sakai C, Inaba T, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000;111:826–34.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the physicians and data managers who contributed valuable data. We also thank the data management committees of the JSHCT.

Funding

This work was supported in part by MEXT KAKENHI Grant Number 16K09875.

Author information

Authors and Affiliations

  1. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan

    Koji Kato

  2. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Takehiko Mori

  3. Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan

    Sung-Won Kim

  4. Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan

    Masashi Sawa

  5. Department of Hematology and Immunology, Kanazawa Medical University, Kanazawa, Japan

    Tomoyuki Sakai

  6. Department of Hematology, Kobe General Hospital, Kobe, Japan

    Hisako Hashimoto

  7. Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Hospital, Nagasaki, Japan

    Jun Taguchi

  8. Division of Hematology and Oncology, Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan

    Tatsuo Oyake

  9. Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan

    Shingo Kurahashi

  10. Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan

    Kazunori Imada

  11. Department of Hematology, Tenri Hospital, Tenri, Japan

    Hitoshi Ohno

  12. Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan

    Junji Tanaka

  13. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Tatsuo Ichinohe

  14. Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta & Ritsuro Suzuki

  15. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  16. Cancer Center, Shimane University Hospital, Izumo, Japan

    Ritsuro Suzuki & Junji Suzumiya

Authors
  1. Koji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takehiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masashi Sawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisako Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuo Oyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shingo Kurahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazunori Imada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hitoshi Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Junji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tatsuo Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Junji Suzumiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Kato.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kato, K., Mori, T., Kim, SW. et al. Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 54, 1515–1517 (2019). https://doi.org/10.1038/s41409-019-0491-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0491-7

This article is cited by

Search

Advanced search

Quick links